Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBIO NASDAQ:INVA NASDAQ:MNKD NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$17.95-1.3%$19.93$8.72▼$27.41$501.26M1.16230,614 shs124,156 shsINVAInnoviva$22.61+0.8%$22.83$16.52▼$25.15$1.65B0.35874,111 shs564,687 shsMNKDMannKind$3.87-3.3%$3.16$2.23▼$6.51$1.24B1.135.07 million shs3.16 million shsNVAXNovavax$9.20-0.1%$9.02$6.13▼$11.97$1.51B2.454.76 million shs4.15 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma-1.32%-0.28%-10.12%+73.43%-97.66%INVAInnoviva+0.85%+0.31%+2.91%+3.29%+3.72%MNKDMannKind-3.25%+8.40%+25.24%+48.28%+1.57%NVAXNovavax-0.11%+6.11%+1.55%-8.09%+30.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$17.95-1.3%$19.93$8.72▼$27.41$501.26M1.16230,614 shs124,156 shsINVAInnoviva$22.61+0.8%$22.83$16.52▼$25.15$1.65B0.35874,111 shs564,687 shsMNKDMannKind$3.87-3.3%$3.16$2.23▼$6.51$1.24B1.135.07 million shs3.16 million shsNVAXNovavax$9.20-0.1%$9.02$6.13▼$11.97$1.51B2.454.76 million shs4.15 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma-1.32%-0.28%-10.12%+73.43%-97.66%INVAInnoviva+0.85%+0.31%+2.91%+3.29%+3.72%MNKDMannKind-3.25%+8.40%+25.24%+48.28%+1.57%NVAXNovavax-0.11%+6.11%+1.55%-8.09%+30.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCrescent Biopharma 3.11Buy$28.0055.99% UpsideINVAInnoviva 2.57Moderate Buy$36.2060.11% UpsideMNKDMannKind 2.60Moderate Buy$8.97131.75% UpsideNVAXNovavax 2.22Hold$13.0041.30% UpsideCurrent Analyst Ratings BreakdownLatest CBIO, INVA, NVAX, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026NVAXNovavax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.006/1/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$11.006/1/2026INVAInnoviva HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.005/26/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.005/13/2026CBIOCrescent Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (D-)5/7/2026NVAXNovavax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/7/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $10.005/7/2026MNKDMannKind HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.005/7/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $42.005/7/2026MNKDMannKind Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$3.50 ➝ $4.755/7/2026MNKDMannKind MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $7.00(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCrescent Biopharma$10.84M45.64N/AN/A$14.32 per share1.25INVAInnoviva$411.33M4.06$5.07 per share4.46$15.71 per share1.44MNKDMannKind$348.97M3.43$0.06 per share64.64($0.17) per share-22.76NVAXNovavax$1.12B1.35$3.51 per share2.62($0.79) per share-11.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCrescent Biopharma-$153.94M-$10.91N/AN/AN/AN/A-103.44%-88.19%7/30/2026 (Estimated)INVAInnoviva$271.17M$6.013.769.30N/A119.89%33.33%22.67%8/5/2026 (Estimated)MNKDMannKind$5.86M-$0.07N/A32.25N/A-6.63%-11.21%-3.92%8/5/2026 (Estimated)NVAXNovavax$440.30M-$0.58N/AN/AN/A-14.73%-14.82%1.23%8/5/2026 (Estimated)Latest CBIO, INVA, NVAX, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026INVAInnoviva$0.43$0.44+$0.01$2.22$101.57 million$97.99 million5/6/2026Q1 2026MNKDMannKind-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 million5/6/2026Q1 2026NVAXNovavax-$0.25-$0.06+$0.19-$0.06$79.81 million$118.90 million4/29/2026Q1 2026CBIOCrescent Biopharma-$0.85-$0.70+$0.15-$0.70$0.36 million$1.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCrescent BiopharmaN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCrescent BiopharmaN/A13.7813.78INVAInnoviva0.1921.1320.07MNKDMannKindN/A1.871.50NVAXNovavaxN/A2.482.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCrescent Biopharma75.19%INVAInnoviva99.12%MNKDMannKind49.55%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipCBIOCrescent Biopharma8.70%INVAInnoviva2.01%MNKDMannKind2.60%NVAXNovavax1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCrescent Biopharma5027.56 million25.16 millionNo DataINVAInnoviva10073.81 million72.33 millionOptionableMNKDMannKind400308.95 million300.92 millionOptionableNVAXNovavax1,990164.44 million161.81 millionOptionableCBIO, INVA, NVAX, and MNKD HeadlinesRecent News About These CompaniesModerna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?June 16 at 3:31 PM | 247wallst.comModerna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?June 16 at 3:21 PM | 247wallst.comA Look Back at Therapeutics Stocks’ Q1 Earnings: Novavax (NASDAQ:NVAX) Vs The Rest Of The PackJune 16 at 2:48 PM | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Novavax (NVAX)June 14 at 8:52 AM | theglobeandmail.comNovavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You TradeJune 12, 2026 | finance.yahoo.comNovavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You TradeJune 12, 2026 | zacks.comNovavax Pivots To Matrix M Licensing As Sanofi Takes EuropeJune 10, 2026 | finance.yahoo.comNovavax rises after six sessions of declineJune 9, 2026 | msn.comNovavax set for a seventh straight declineJune 9, 2026 | msn.comNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowJune 8, 2026 | finance.yahoo.comNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowJune 8, 2026 | zacks.comNovavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue?June 5, 2026 | finance.yahoo.comNovavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue?June 5, 2026 | zacks.comNovavax’s Combo COVID-19 and Flu Shot Trial Reaches Key Milestone for Older AdultsJune 5, 2026 | tipranks.com3 Cash-Burning Stocks We Think Twice AboutJune 4, 2026 | finance.yahoo.comNovavax, Inc. (NVAX) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 4, 2026 | seekingalpha.comNovavax Inc. stock underperforms Monday when compared to competitorsJune 1, 2026 | marketwatch.comNovavax to Participate in 2026 Jefferies Global Healthcare ConferenceJune 1, 2026 | finance.yahoo.comNovavax to Participate in 2026 Jefferies Global Healthcare ConferenceJune 1, 2026 | prnewswire.comNovavax: The Pivot To A Royalty Model Is Working, But It's Still A HoldMay 30, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBIO, INVA, NVAX, and MNKD Company DescriptionsCrescent Biopharma NASDAQ:CBIO$17.95 -0.24 (-1.32%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$18.11 +0.16 (+0.89%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Innoviva NASDAQ:INVA$22.61 +0.19 (+0.85%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$22.65 +0.04 (+0.18%) As of 05:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.MannKind NASDAQ:MNKD$3.87 -0.13 (-3.25%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$3.89 +0.02 (+0.52%) As of 06:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Novavax NASDAQ:NVAX$9.20 -0.01 (-0.11%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$9.26 +0.06 (+0.60%) As of 06:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
